Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

The architecture of the IgG anti-carbohydrate repertoire in primary antibody deficiencies

Peter Jandus, Kayluz Frias Boligan, David F. Smith, Elisabeth de Graauw, Bodo Grimbacher, Camilla Jandus, Mai M. Abdelhafez, Alain Despont, Nicolai Bovin, Dagmar Simon, Robert Rieben, Hans-Uwe Simon, Richard D. Cummings, Stephan von Gunten

Blood (2019) 134 (22): 1941–1950.

https://doi.org/10.1182/blood.2019001705

Published: 2019

Includes: Supplemental data

Journal Articles

Rezafungin Prevention of Pneumocystis Pneumonia and Pneumocystis reactivation Using Different Doses and Durations of Prophylaxis in a Mouse Model

Melanie T Cushion, PhD MS, Alan Ashbaugh, Voon Ong, PhD

Blood (2019) 134 (Supplement_1): 3266.

https://doi.org/10.1182/blood-2019-127392

Published: 2019

Journal Articles

Quantitative Integrative Prediction of Survival Probability in Multiple Myeloma Using Molecular and Clinical Prognostic Factors in 657 Patients Treated with Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation

Manuela Hummel, Thomas Hielscher, Hans Jürgen Salwender, MD, Christof Scheid, Hans Martin, MD, Uta Bertsch, MD, Hartmut Goldschmidt, MD, Anja Seckinger, Dirk Hose, MD

Blood (2018) 132 (Supplement 1): 403.

https://doi.org/10.1182/blood-2018-99-113307

Published: 2018

Journal Articles

Extracellular Microvesicle Cytokines Secreted from Bone Marrow Mesenchymal Cells Mediate Proliferative and Survival Advantage in Acute Myeloid Leukaemia

Michelle Lazenby, BSc, Oliver G. Ottmann, MD, Keith Wilson, FRCPath, MRCP, MBBS, Caroline Alvares, MBBS, PhD, Joanna Zabkiewicz, PhD

Blood (2018) 132 (Supplement 1): 2744.

https://doi.org/10.1182/blood-2018-99-113342

Published: 2018

Journal Articles

Initial Evaluation of Adolescent Females Hospitalized with Heavy Menstrual Bleeding

Lauren E Amos, MD, Shannon L Carpenter, MD

Blood (2018) 132 (Supplement 1): 1216.

https://doi.org/10.1182/blood-2018-99-119576

Published: 2018

Journal Articles

Heavy Menstrual Bleeding in Adolescent Females with Platelet Function Disorders

Lauren E Amos, MD, Shannon L Carpenter, MD

Blood (2018) 132 (Supplement 1): 4980.

https://doi.org/10.1182/blood-2018-99-119370

Published: 2018

Journal Articles

Towards an External Quality Assessment for Next Generation Sequencing in the Diagnosis of Rare Inherited Anaemias

Blood (2018) 132 (Supplement 1): 4936.

https://doi.org/10.1182/blood-2018-99-111609

Published: 2018

Journal Articles

Primary Antibody Deficiencies: Scientific Discoveries Leading to Challenging Paradigms in a Complex Disease Landscape

Anne Durandy, MD PhD, Sven Kracker, PhD, Marina Cavazzana, MD PhD

Blood (2017) 130 (Supplement 1): SCI-28.

https://doi.org/10.1182/blood.V130.Suppl_1.SCI-28.SCI-28

Published: 2017

Journal Articles

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Blood (2017) 130 (Supplement 1): 2016.

https://doi.org/10.1182/blood.V130.Suppl_1.2016.2016

Published: 2017

Journal Articles

Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial

Blood (2017) 130 (Supplement 1): 400.

https://doi.org/10.1182/blood.V130.Suppl_1.400.400

Published: 2017

Journal Articles

Bortezomib, Liposome Doxorubicin and Dexamethasone (PDd) Is Superior in Safety and Not Inferior in Efficiency to Bortezomib, Doxorubicin and Dexamethasone (PAd) As Induction Therapy in New-Diagnosed Multiple Myeloma Patients: An Interim Report from China's Multicenter Study

Song Jin, Yun Xu, Jin Zhou, Jingjing Shang, Lingzhi Yan, Chengcheng Fu, Depei Wu, MD

Blood (2017) 130 (Supplement 1): 5433.

https://doi.org/10.1182/blood.V130.Suppl_1.5433.5433

Published: 2017

Journal Articles

Efficacy of CD101, a Novel Echinocandin, in Prevention of Pneumocystis Pneumonia (PCP): Thwarting the Biphasic Life Cycle of Pneumocystis

Melanie Cushion, Alan Ashbaugh, Keeley Lynch, Michael J. Linke, Ken Bartizal, PhD

Blood (2016) 128 (22): 3396.

https://doi.org/10.1182/blood.V128.22.3396.3396

Published: 2016

Journal Articles

Potential Targeting Ph + Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity

Justine Yu, B.S., Giovannino Silvestri, PhD, Lorenzo Stramucci, PhD, Masashi Sanada, MD PhD, Tomoyuki Yamaguchi, PhD, Yang Du, PhD, Jukka Westermarck, MD PhD, Michael A. Caligiuri, MD, Ramiro Garzon, MD, Dragana Milojkovic, MD, Jane F. Apperley, MD, Denis-Claude Roy, MD, Guido Marcucci, MD, Bruno Calabretta, MD PhD, Maria R. Baer, MD, Rossana Trotta, PhD, Danilo Perrotti, MD PhD

Blood (2016) 128 (22): 2909.

https://doi.org/10.1182/blood.V128.22.2909.2909

Published: 2016

Journal Articles

Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma

Maximilian Merz, MD, Hans-Juergen Salwender, MD, Mathias Haenel, MD, Uta Bertsch, MD, Christina Kunz, Thomas Hielscher, Igor W. Blau, MD, Christof Scheid, MDPhD, Elias Karl Mai, MD, Dirk Hose, MD, Bärbel Schurich, Markus Munder, MD, Peter Brossart, MD, Christian Gerecke, MD, Hans Walter Lindemann, MD, Matthias Zeis, MD, Katja C. Weisel, Jan Duerig, MD, Hartmut Goldschmidt, MD

Blood (2015) 126 (23): 4233.

https://doi.org/10.1182/blood.V126.23.4233.4233

Published: 2015

Journal Articles

Voriconazole Increase the Risk of PN in Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy

Yan Xu, MDPhD, Shuhui Deng, MD, Gang An, MDPhD, Zengjun Li, Sr., Xiaoqi Qin, MD, Weiwei Sui, MD, Xiaoyan Feng, Dehui Zou, Lugui Qiu, MD PhD

Blood (2015) 126 (23): 5394.

https://doi.org/10.1182/blood.V126.23.5394.5394

Published: 2015

Journal Articles

Prevalence and Risk Factors of Iron Deficiency Anemia Amongst High Risk Health Care Workers in Udonthani Hospital, Thailand

Saranya Pongudom, MD, Adisak Tantiworawit, MD

Blood (2015) 126 (23): 5590.

https://doi.org/10.1182/blood.V126.23.5590.5590

Published: 2015

Journal Articles

Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4

Elias Karl Mai, MD, Christina Kunz, PhD, Uta Bertsch, MD, Hans-Juergen Salwender, MD, Michael Pfreundschuh, MD, Ulrich Duehrsen, MD, Peter Brossart, MD, Norma Peter, MD, Kai Neben, MD, Thomas Hielscher, Jens Hillengass, MD, Hans Martin, MD, Hans Walter Lindemann, MD, Christof Scheid, MD PhD, Katja C. Weisel, Igor W. Blau, MD, Hartmut Goldschmidt, MD

Blood (2015) 126 (23): 3187.

https://doi.org/10.1182/blood.V126.23.3187.3187

Published: 2015

Journal Articles

Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial

Maximilian Merz, MD, Hans Salwender, MD, Mathias Hänel, MD, Uta Bertsch, MD, Christina Kunz, PhD, Thomas Hielscher, Igor W. Blau, MD, Christof Scheid, MDPhD, Elias Karl Mai, MD, Dirk Hose, MD, Baerbel Schurich, PhD, Markus Munder, MD, Ingo GH Schmidt-Wolf, MD, Christian Gerecke, MD, Hans Walter Lindemann, MD, Matthias Zeis, MD, Katja Weisel, MD, Jan Duerig, MD, Hartmut Goldschmidt, MD

Blood (2014) 124 (21): 3475.

https://doi.org/10.1182/blood.V124.21.3475.3475

Published: 2014

Journal Articles

Bone Turnover In Multiple Myeloma: Impact Of Bortezomib-Based Induction Therapy, High-Dose Melphalan, and Lenalidomide Consolidation On Osteoblast and Osteoclast Function Within The GMMG-MM5 Trial

Anja Seckinger, MD, Tobias Meißner, PhD, Uta Bertsch, MD, Hans Salwender, MD, Jan Dürig, MD, Mathias Hänel, MD, Igor W. Blau, MD, Christof Scheid, MD, Katja Weisel, MD, Bernard Klein, PhD, Hartmut Goldschmidt, MD, Dirk Hose, Dr. med. dipl.-phys.

Blood (2013) 122 (21): 1863.

https://doi.org/10.1182/blood.V122.21.1863.1863

Published: 2013

Journal Articles

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

Blood (2013) 122 (21): 1897.

https://doi.org/10.1182/blood.V122.21.1897.1897

Published: 2013

NARROW

The architecture of the IgG anti-carbohydrate repertoire in primary antibody deficiencies

Rezafungin Prevention of Pneumocystis Pneumonia and Pneumocystis reactivation Using Different Doses and Durations of Prophylaxis in a Mouse Model

Quantitative Integrative Prediction of Survival Probability in Multiple Myeloma Using Molecular and Clinical Prognostic Factors in 657 Patients Treated with Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation

Extracellular Microvesicle Cytokines Secreted from Bone Marrow Mesenchymal Cells Mediate Proliferative and Survival Advantage in Acute Myeloid Leukaemia

Initial Evaluation of Adolescent Females Hospitalized with Heavy Menstrual Bleeding

Heavy Menstrual Bleeding in Adolescent Females with Platelet Function Disorders

Towards an External Quality Assessment for Next Generation Sequencing in the Diagnosis of Rare Inherited Anaemias

Primary Antibody Deficiencies: Scientific Discoveries Leading to Challenging Paradigms in a Complex Disease Landscape

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial

Bortezomib, Liposome Doxorubicin and Dexamethasone (PDd) Is Superior in Safety and Not Inferior in Efficiency to Bortezomib, Doxorubicin and Dexamethasone (PAd) As Induction Therapy in New-Diagnosed Multiple Myeloma Patients: An Interim Report from China's Multicenter Study

Efficacy of CD101, a Novel Echinocandin, in Prevention of Pneumocystis Pneumonia (PCP): Thwarting the Biphasic Life Cycle of Pneumocystis

Potential Targeting Ph + Acute Lymphoblastic Leukemia Stem and Progenitor Cells By Modulating the CIP2A-SET-SETBP1 -Mediated Suppression of PP2A Activity

Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma

Voriconazole Increase the Risk of PN in Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy

Prevalence and Risk Factors of Iron Deficiency Anemia Amongst High Risk Health Care Workers in Udonthani Hospital, Thailand

Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4

Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial

Bone Turnover In Multiple Myeloma: Impact Of Bortezomib-Based Induction Therapy, High-Dose Melphalan, and Lenalidomide Consolidation On Osteoblast and Osteoclast Function Within The GMMG-MM5 Trial

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only